A new chemotherapeutic investigation: Piracetam effects on dyslexia |
| |
Authors: | Christopher H Chase R Larry Schmitt Guy Russell Paula Tallal |
| |
Institution: | (1) Children’s Hospital and Health Center, San Diego, California |
| |
Abstract: | Piracetam, a new drug which is thought to enhance learning and memory consolidation, was given in a 3300 mg daily dose to
half of a group of fifty-five (55) dyslexic boys aged eight to thirteen years in a twelve week, double-blind, placebo controlled
study. All subjects met stringent criteria, including: normal intelligence, normal educational opportunities, no severe emotional
problems, no neurological handicaps, good physical health, not taking other psychotropic medication, and scoring at least
1 1/2 years below their mental age equivalent on the Gilmore Oral Reading Test. The children’s perceptual, language, and memory
skills were examined and their reading, spelling, and writing abilities were measured using standardized instruments. Compared
to the placebo control group, individuals treated with Piracetam showed statistically significant improvements above their
baseline scores on measures of effective reading accuracy and comprehension, reading speed, and writing accuracy. The medication
was extremely well tolerated, and all medical examinations showed no untoward effects. These results encourage further study
of Piracetam’s potential as an adjunct for the clinical remediation of dyslexia. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|